

# What's new in the Pre-exposure prophylaxis (PrEP) against HIV topic (2023)

Some of the new information and major changes included in *Therapeutic Guidelines*.

---

To align with the updated Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) PrEP guidelines, *Therapeutic Guidelines* undertook a full revision of the Pre-exposure prophylaxis (PrEP) topic. PrEP is now recommended for all people at risk of HIV infection, and should be considered for any person requesting PrEP or who would benefit from PrEP (eg because of anxiety).

The new topic helps guide the discussion of a person's sexual health and behaviour to determine their **suitability for HIV PrEP**. When assessing a person's suitability for HIV PrEP, prescribers are advised to take into account the person's HIV acquisition risk in the previous 3 months as well as their expected HIV acquisition risk in the next 3 months. A new section on assessing the risk of HIV acquisition in women who have sex with women has also been added.

The section on **Antiretroviral regimens for HIV PrEP** now includes advice for prescribing tenofovir disoproxil succinate+emtricitabine (a new generic form of tenofovir disoproxil+emtricitabine). The prescribing advice for on-demand HIV PrEP has been updated and provides more guidance on when and how this regimen can be used. Advice on the safest way to stop PrEP, if required, is also included.

---

For more information and orders visit [www.tg.org.au](http://www.tg.org.au) or freecall 1800 061 260 (within Australia)



Therapeutic  
Guidelines

For computers and mobile devices



Download the Therapeutic Guidelines app

June 2023

# What's new in the Arthroplasty device infections topic (2022)

Some of the new information and major changes included in *Therapeutic Guidelines*.

---

To address the findings of the landmark PIANO<sup>1</sup> study, Therapeutic Guidelines undertook a full revision of the Arthroplasty device infections topic. The study confirmed that aetiology of arthroplasty device infections varies depending on the classification of the infection, which has important implications for empirical antibiotic treatment.

The new topic includes a useful overview section on **Approach to managing arthroplasty device infections**, which links to more detailed information on investigations, surgical management and antibiotic therapy. A key point highlighted in this section is the need to urgently refer any patient with a suspected arthroplasty device infection to the surgeon who implanted the joint. Early multidisciplinary input, involving both a surgeon experienced in arthroplasty and an infectious diseases physician or clinical microbiologist, is essential to guide investigations and management of arthroplasty device infections.

The section on **Investigations** includes a discussion on the importance of withholding empirical antibiotic therapy preoperatively to optimise the microbiological yield of surgical peri-prosthetic sampling in patients without sepsis or sepsis shock. Surgical antibiotic prophylaxis is still recommended to be administered at the usual time before surgical incision to decrease the risk of surgical site infection.

The section on **Surgical management** has been updated in line with the latest evidence, including the duration of antibiotic therapy for different surgical strategies and advice on the appropriateness of each strategy based on the classification of the infection and other patient factors.

---

<sup>1</sup> Manning L, Metcalf S, Clark B, Robinson JO, Huggan P, Luey C, et al. Clinical Characteristics, Etiology and Initial Management Strategy of Newly Diagnosed Periprosthetic Joint Infection: A Multicenter, Prospective Observational Cohort Study of 783 Patients. *Open Forum Infect Dis* 2020;7(5)ofaa068. <https://www.ncbi.nlm.nih.gov/pubmed/32432148>

Arthroplasty device infections are classified as early postoperative, late acute or late chronic infections according to the timing of the infection following joint implantation and the duration of symptoms. Narrow-spectrum **empirical antibiotic treatment** is recommended for late acute infections, which are mainly caused by Gram-positive organisms. In contrast, broad-spectrum empirical antibiotic treatment is required to treat the likely pathogens implicated in early postoperative and late chronic infections, and for any patients with symptoms or signs of sepsis or septic shock. **Directed antibiotic therapy** is based on culture and susceptibility results from intraoperative sampling; the new topic highlights evidence suggesting an early switch to oral therapy is appropriate for the majority of patients.

---

**For more information and orders visit [www.tg.org.au](http://www.tg.org.au)  
or freecall 1800 061 260 (within Australia)**



**Therapeutic  
Guidelines**

For computers and mobile devices



Download the Therapeutic Guidelines app

August 2022

# What's new in the Sore throat and Acute rheumatic fever topics (2022)

Some of the new information and major changes included in *Therapeutic Guidelines*.

---

Therapeutic Guidelines is committed to updating clinical advice between regular revisions in response to significant shifts in evidence or clinical practice. In March 2021, Therapeutic Guidelines put together a dedicated expert group to completely revise the **Sore throat** and **Acute rheumatic fever** topics in response to the publication of *The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease* by RHD Australia.

## Sore throat

Sore throat is one of the most frequent presentations in primary care and, despite the most common causes being viral pharyngitis and tonsillitis, sore throat remains a common reason for prescribing antibiotics. The newly revised Sore throat topic aims to clearly define the patients who always require empirical antibiotic therapy for streptococcal pharyngitis and tonsillitis, and to explain why most other patients do not require antibiotics.

Management of pharyngitis and tonsillitis is now stratified based on whether or not patients are at high risk of acute rheumatic fever. Empirical antibiotic therapy is recommended for all patients at high risk of acute rheumatic fever, even if their clinical features suggest that a viral infection is likely, because the increased risk of acute rheumatic fever and resultant rheumatic heart disease outweighs the risk of harms from potentially unnecessary antibiotic treatment in these patients. In patients not at high risk of acute rheumatic fever, even when a bacterial cause of pharyngitis or tonsillitis is likely, antibiotic therapy is of limited benefit and is not required for most patients.

The **algorithm for assessing and managing acute sore throat** is a helpful tool for navigating the Sore throat topic, and the **summary table of causes of sore throat** helps ensure that less common causes are not missed. To aid decisions on management, detailed advice is given on **assessing the risk of acute rheumatic fever**, and common clinical questions on the **role of clinical features in distinguishing between a viral and streptococcal infection**, and **investigations for pharyngitis and tonsillitis** are answered.

For patients who require **antibiotic therapy for streptococcal pharyngitis or tonsillitis**, phenoxymethylpenicillin is still recommended first-line, but the option of using amoxicillin is now included for children unable to tolerate the liquid formulation of phenoxymethylpenicillin. For patients who do not require antibiotic therapy, the **shared-decision making framework** can be used to discuss the evidence for the potential benefits and harms of therapy, and address patient expectations of antibiotics.

### **Acute rheumatic fever**

Acute rheumatic fever is a significant nonsuppurative complication of streptococcal infection. The revised topic includes a discussion on the epidemiology of acute rheumatic fever, and highlights the importance of advocacy and social interventions to address the high incidence of acute rheumatic fever in Aboriginal and Torres Strait Islander peoples.

Updated criteria for **diagnosis of acute rheumatic fever** aim to avoid missing the diagnosis in high-risk patients while minimising overdiagnosis in those at lower risk. The sections on **acute treatment and prevention of recurrent acute rheumatic fever** emphasise the need for health services to work with patients to ensure acceptable and successful secondary prophylaxis with benzathine benzylpenicillin.

---

**For more information and orders visit [www.tg.org.au](http://www.tg.org.au)  
or freecall 1800 061 260 (within Australia)**



Download the Therapeutic Guidelines app

# What's new in Antibiotic 16 (2019)

## Some of the new information and major changes included in *Therapeutic Guidelines: Antibiotic*, version 16.

The Antibiotic Guidelines have been extensively revised and include more content than ever. They provide practical advice on managing a wide range of infections, from self-limiting infections usually managed in primary care (eg acute bronchitis, acute otitis media) to severe infections requiring treatment in hospital (eg meningitis, sepsis).

A selection of significant changes is described below.

In response to feedback, the guidelines have been reorganised to reintroduce an alphabetical table of contents. However, for ease of navigation, the table of contents groups some topics by subject area—to see the topics available within a subject area, simply click on the plus sign to expand the table of contents.

New resources have been included to support primary care practitioners seeking to reduce inappropriate antimicrobial use (eg prescribing broad-spectrum antibiotics for infections where narrower-spectrum antibiotics are effective; using antibiotics for viral or self-limiting infections). These include:

- templates for **shared decision making** (printable from *eTG complete*), which aid collaborative decisions between doctors and their patients about the management of common, self-limiting infections (ie acute bronchitis, acute otitis media, acute rhinosinusitis, exacerbations of chronic obstructive pulmonary disease, streptococcal pharyngitis or tonsillitis)
- tables or flowcharts to help differentiate bacterial from viral infection for conditions for which antibiotics are overprescribed (eg acute rhinosinusitis, sore throat, conjunctivitis)
- clear statements on investigations or treatments to avoid because they do not offer a benefit or may result in harm
- information on **antimicrobial stewardship** in the community setting, including strategies for general practice and residential aged-care facilities
- topics on acute bronchitis, acute laryngitis and protracted bacterial bronchitis.

The guidelines provide clear advice to help practitioners select the appropriate management for their patient when this depends on infection severity and patient-specific factors (eg antimicrobial hypersensitivity, likelihood of infection with a multidrug-resistant pathogen, social circumstances). The following common clinical questions are addressed:

- **When should initial oral therapy be used for hospitalised patients?**

In some circumstances, it is appropriate to treat hospitalised patients with oral therapy initially. For example, children with moderate-severity community-acquired pneumonia, and adults with low-severity community-acquired pneumonia who have been admitted to hospital because of their social circumstances.

- **When is it appropriate to switch from intravenous to oral therapy?**

The criteria that should be met before switching from intravenous to oral therapy are summarised in a new box. For some infections (eg cellulitis associated with systemic symptoms), one or two doses of intravenous therapy is sufficient when systemic symptoms resolve rapidly; oral therapy is appropriate for the remainder of the treatment course.

- **What is the appropriate duration of therapy?**

The shortest possible duration of therapy should be used, consistent with the condition being treated and the patient's clinical response. Condition-specific advice is included in each topic.

- **Have treatment recommendations changed because of increased antimicrobial resistance?**

The antimicrobial regimens recommended in these guidelines are informed by available resistance data. Increased rates of antimicrobial resistance have required changes to the empirical regimens recommended for some infections, including *Shigella* enteritis, *Neisseria meningitidis* meningitis and meningococcaemia, community-acquired pneumonia, and urinary tract infections. In some circumstances, dose, rather than antimicrobial choice, has been adjusted to address resistance.

- **How do I assess my patient's risk of infection with a resistant pathogen?**

For some infections the empirical regimen should be adjusted if the patient is at risk of infection with a resistant pathogen; however, it can be difficult to gauge an individual patient's risk. To help practitioners with their assessment, the most pertinent risk factors for infection with methicillin-resistant *Staphylococcus aureus* or multidrug-resistant Gram-negative bacteria have been summarised in user-friendly boxes.

- **Which antibiotics should I use if my patient is hypersensitive to penicillins?**

Based on improved knowledge of beta-lactam cross-reactivity, the approach to managing patients with penicillin hypersensitivity has changed significantly, allowing increased cephalosporin use in some circumstances. Antibiotic recommendations for these patients are now based on the severity (nonsevere or severe) of the reaction, in addition to the timing of its onset (immediate or delayed). Details are provided in the 'Antimicrobial hypersensitivity' topic.

- **What changes do I need to make if my patient is critically ill?**

Treatment recommendations for common sources of sepsis are included throughout these guidelines.

Modified dosing regimens are now routinely recommended for patients with septic shock or requiring intensive care support treated with drugs whose pharmacokinetics are altered in critically ill patients (eg ceftriaxone, gentamicin, vancomycin).

- **Which common antimicrobials are used differently in children than in adults?**

The availability and tolerability of oral liquid antibiotic formulations has been considered when making recommendations.

Updated safety advice on the use of quinolones and doxycycline has been included. Quinolones are not licensed for use in children on the basis of animal studies that showed an adverse effect on cartilage development with quinolone use; however, there are few data from human trials to support this finding. A quinolone can be used in children when it is the drug of choice. Doxycycline has not been associated with tooth discolouration, enamel hypoplasia or bone deposition, even in children younger than 8 years, so is increasingly used in this age group. However, use is limited by the lack of a suitable formulation. Practical doxycycline doses have been included for children 8 years or older.



Practice-changing revisions include:

- Prompt intervention, including administration of antibiotics, is crucial for patients with suspected **sepsis or septic shock**. New antibiotic recommendations are included for use by community-based practitioners when the patient's arrival at a hospital is likely to be delayed by 1 hour or more.
- Gentamicin-based regimens remain the treatment of choice for several serious infections (eg sepsis, intra-abdominal infections). Dosing is complex, so a table of calculated initial **gentamicin** doses for adults has been included to aid timely prescription of the appropriate dose.
- Guidance on the role of antibiotic prophylaxis to **prevent infective endocarditis** has been simplified. Prophylaxis is only recommended for patients with specific cardiac conditions who are undergoing a procedure associated with a high risk of a bacteraemia that is associated with endocarditis. These conditions and procedures are summarised in 2 boxes (printable from eTG complete).
- The '**Gastrointestinal protozoa**' topic discusses the controversial nature of *Blastocystis hominis* and *Dientamoeba fragilis* pathogenicity, with advice on how to manage a patient with a positive test.
- A positive microbiological test for *Chlamydia trachomatis*, *Mycoplasma genitalium* or *Neisseria gonorrhoeae* is not uncommon in asymptomatic sexual contacts of patients with known infection. Practitioners can now refer to the management advice for **asymptomatic sexually-transmitted infections** in three new topics.
- New recommendations are included for **HIV** pre-exposure prophylaxis (PrEP) and expanded recommendations are included for initial treatment of HIV infection (including regimens for patients with hepatitis B virus co-infection). A new table summarises antiretroviral choice for patients with suspected or confirmed exposure to HIV, based on the type of exposure and HIV status of the source.
- **Surgical antibiotic prophylaxis** is the most common indication for antibiotic use in hospitals. New, easy-to-use summary tables provide clear guidance on when prophylaxis is or is not indicated. The topic now includes recommendations for skin and soft tissue surgery, ear, nose and throat surgery, oral maxillofacial surgery and infertility diagnostic procedures.
- It is now recommended that **aspiration pneumonia** be managed initially as per community- or hospital-acquired pneumonia. Most cases of pneumonia develop due to aspiration of bacteria from the oropharynx, so empirical community- or hospital-acquired pneumonia regimens in these guidelines treat the relevant pathogens.
- Three-times-weekly therapy has a diminished role in the treatment of **tuberculosis**. Details are provided in the 'Tuberculosis' topic. For latent tuberculosis there are new options for drug therapy, and information on additional considerations in immunocompromised patients.

- The '**Community-based parenteral antimicrobial therapy**' topic has been extensively revised in response to feedback from users. While practice varies around Australia, this topic sets a standard of care that applies to all patients receiving community-based therapy, regardless of how it is delivered.
- Situations in which **antimicrobial desensitisation** is the preferred option for management are now highlighted throughout the guideline (eg for penicillin-hypersensitive patients with streptococcal endocarditis, because benzylpenicillin is the treatment of choice). There are new beta-lactam desensitisation protocols, including one for amoxicillin.

New content has also been included on:

- empirical therapy for neonates with early-onset or late, community-onset sepsis or septic shock when the source of infection is not known
- intramuscular administration of antimicrobials for neonates or children with sepsis or septic shock in whom intravenous access cannot be established
- acute mastoiditis
- prevention of invasive group A streptococcal infection
- prophylaxis for medicinal leech therapy
- retropharyngeal abscess
- pre-emptive treatment following a penetrating eye injury
- treatment of perinatal infections, including intra-amniotic infection (chorioamnionitis), postpartum endometritis and septic abortion
- the role of intravenous amoxicillin+clavulanate in pharyngeal infections, intra-abdominal infections, respiratory tract infections (including hospital-acquired pneumonia), skin and soft tissue infections, and wound infections
- directed therapy for *Streptococcus pneumoniae* sepsis or septic shock.

For more information and orders visit [www.tg.org.au](http://www.tg.org.au) or freecall 1800 061 260 (within Australia)